Remove .Net Remove 2019 Remove Pricing Remove Report
article thumbnail

10 Realities Today Cause Startups To Bypass An IPO

Startup Professionals Musings

According to a recent Ernst & Young global report , the first half 2019 global IPO activity slowdown continued, following an unusually quiet Q1 2019 as ongoing geopolitical tensions and trade issues dampened IPO sentiment. Public companies of any size must comply immediately with the full reporting requirements of the SEC.

Startup 84
article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. It was the tweet heard around the biotech world, again.

Pricing 40